<DOC>
	<DOCNO>NCT01663623</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety belimumab , combination azathioprine , maintenance remission follow standard induction regimen patient Wegener 's granulomatosis microscopic polyangiitis . The random assignment study `` 1 1 '' mean participant equal chance receive belimumab placebo .</brief_summary>
	<brief_title>Belimumab Remission VASculitis</brief_title>
	<detailed_description />
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>Key Clinical diagnosis Wegener 's granulomatosis microscopic polyangiitis Chapel Hill criterion . Disease flare past 26 week require treatment high dose corticosteroid 1 follow medication : rituximab , oral cyclophosphamide OR IV cyclophosphamide . Tested positive antiproteinase 3 ( antiPR3 ) antimyeloperoxidase ( antiMPO ) antibody time prior enrollment . Achieve remission 26 week first dose induction treatment . Remission define Birmingham Vasculitis Activity ( BVAS ) score 0 receive less 10 mg/day oral prednisone ( equivalent ) 2 consecutive visit 21 35 day apart . Maintenance therapy study must start 2 week confirmation remission . Key Pregnant nursing . Receipt B cell target therapy ( rituximab ) anytime Receipt investigational biological agent within past 60 day . Required management acute chronic infection within past 60 day . Current drug alcohol abuse dependence . Current past positive test human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C. History severe allergic reaction contrast agent biological medicine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Wegener 's Granulomatosis</keyword>
	<keyword>anti-MPO</keyword>
	<keyword>WG</keyword>
	<keyword>Belimumab</keyword>
	<keyword>GPA</keyword>
	<keyword>anti-proteinase 3</keyword>
	<keyword>anti-neutrophil cytoplasmic antibody</keyword>
	<keyword>anti-myeloperoxidase</keyword>
	<keyword>Granulomatosis polyangiitis</keyword>
	<keyword>Vasculitis</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Microscopic Polyangiitis</keyword>
	<keyword>anti-PR3</keyword>
	<keyword>ANCA</keyword>
	<keyword>MPA</keyword>
	<keyword>Systemic Vasculitis</keyword>
</DOC>